The call AVOID / SHORT AON — sell or short $332–348 · target $298 · invalidation weekly close > $355.50 · 1–3 months · HIGH CONVICTION. Accumulation zone is $290–305, not $330.
Why now Aon ($329.77, −7.21%) is buying USI for $17.0bn, funded entirely with new debt, taking leverage from 2.9x to 4.8x and suspending buybacks for two years.
The disagreement Consensus is reading a 14.5x multiple and a growth story. That 14.5x is struck on synergized EBITDA — synergies that don't exist applied to earnings that already happened. Strip them out and Aon paid ~21x standalone, versus 14.3x Gallagher paid for AssuredPartners and ~12x Brown & Brown paid for Accession. Aon paid the highest price of the entire broker roll-up, in the eighth quarter of a softening rate cycle.
The level that changes everything A 6.22% blended coupon. Above it, this deal is permanently EPS-dilutive even at 100% synergy capture. Aon's own 2054 notes carry 5.75% and the 30-year Treasury is at 5.262% today. Aon must fund short and pray.
The $16.7bn net price is ~21x USI's actual, current EBITDA — not 14.5x. Here is the arithmetic, which takes thirty seconds and which nobody ran this morning.
Aon's 8-K, filed 06:37 ET, states the net purchase price of $16.7bn represents "approximately 14.5x on a synergized trailing twelve-month adjusted EBITDA basis," with synergized adjusted EBITDA of $1.2bn and net synergies of $395m. Back out the synergies:
| Derivation | Implied standalone EBITDA | Multiple on $16.7bn |
|---|---|---|
| Using the rounded $1.2bn disclosed | $1,200m − $395m = $805m | 20.7x |
| Using the exact figure implied by 14.5x ($16.7bn ÷ 14.5) | $1,152m − $395m = $757m | 22.1x |
| Adding the $1.11bn of transaction, integration and retention cash costs | midpoint $781m | 22.8x |
Call it ~21x standalone, ~23x all-in. The construction being used here is unusual and worth naming precisely: trailing twelve-month EBITDA, adjusted upward by synergies that Aon says will be "substantially realized between the anticipated closing and 2029." Historical earnings, future benefits, one ratio. Aon's own non-GAAP note concedes this presentation "has not been prepared in conformance with the applicable requirements of Regulation S-X relating to pro forma financial information."
Two consequences. First, the 14.5x that will appear in every note tomorrow is not comparable to the multiples in the deals it will be compared against. Second — and this is the tell — if the standalone multiple looked defensible, Aon would have shown it. Gallagher showed both: 14.3x gross and 11.3x net on AssuredPartners. Aon showed one.
Aon is paying a 28% premium to Gallagher's post-synergy multiple and a 47% premium on the pre-synergy basis — for the same category of asset, one cycle-year later.
| Deal | Date | Size | Pre-synergy | Post-synergy |
|---|---|---|---|---|
| Aon – USI | Aug 2026 | $17.0bn | ~21x | 14.5x |
| Aon – NFP | Dec 2023 | ~$13.4bn | — | ~15x* |
| Gallagher – AssuredPartners | Dec 2024 | $13.45bn | 14.3x | 11.3x |
| Brown & Brown – Accession | Jun 2025 | $9.83bn | — | ~12x |
| Marsh McLennan – McGriff | Sep 2024 | $7.75bn | n/d | n/d |
*Seller-adjusted estimated EBITDA at closing. Comps compiled by Insurance Business; basis differs by deal, which is exactly the point.
There is a structural reason multiples should be falling, not rising, across this table. Fitch counted $60bn across five large broker deals in 24 months, against $2–20bn per year over 2013–2023 — and explicitly warned that "M&A can mask underlying deterioration in core business performance." The acquisition wave was financed on cheap debt into a hard pricing market. Both of those conditions have now reversed. Aon is buying at the top of the multiple range at the bottom of the pricing cycle.
At a 5.7% blended coupon, USI's entire standalone profit stream plus 76% of the synergy target is consumed by interest before a single cent reaches shareholders. Full model in Appendix B; the load-bearing arithmetic is here.
That is the return on 4.8x leverage, two years of suspended buybacks, $1.11bn of cash costs and a full integration of 10,500 people. Management's "accretive to adjusted EPS in 2028 and thereafter" is technically true and economically trivial.
Set full-synergy contribution equal to interest: ($730m + $395m) ÷ $18,100m = 6.22%.
Above a 6.22% blended coupon, this transaction never accretes — not in 2028, not ever, not even with 100% synergy capture. Sensitivity:
| Blended coupon | Annual interest | Full-synergy EPS impact | Verdict |
|---|---|---|---|
| 5.00% | $905m | +$0.79 (+3.9%) | Deal works |
| 5.70% (my base) | $1,032m | +$0.33 (+1.7%) | Barely worth doing |
| 6.00% | $1,086m | +$0.14 (+0.7%) | Rounding error |
| 6.22% | $1,125m | $0.00 | Break-even |
| 6.50% | $1,177m | −$0.19 (−0.9%) | Permanently dilutive |
Every 50bp on the blended coupon is worth $90m pre-tax, or $0.32 per share. Now look at where Aon's own paper trades: the 5.750% notes due 2054 and 5.450% due 2034 are listed on the cover of today's 8-K. The 30-year Treasury closed at 5.262% today and the 10-year at 4.763%, with S&P's Q3 2026 credit trends showing 10-year IG spreads widening from 82.6bp to 105.8bp. New 30-year A-/Baa2 paper prices at roughly 6.2–6.3% today. The long end of Aon's own capital stack is already sitting at the break-even coupon.
To hold the blended coupon under 6.22%, Aon must skew ~$18bn of issuance toward 3-, 5- and 7-year paper at 5.0–5.5%. That does two things it will not want to advertise. It builds an $18bn maturity wall in 2029–2033 — precisely the window when the integration is supposed to be finishing and the synergies finally arriving. And front-loaded maturity profiles are exactly what rating agencies penalise in a levered issuer. Term it long and the deal never accretes; term it short and you carry 4.8x against a refinancing cliff. There is no third door.
Third-order: this is the template for the rest of the sector. The financing arbitrage that funded $60bn of broker M&A in two years is closing on rising rates and widening spreads. My opinion: Aon–USI is the last megadeal of this cycle, and it was struck at the worst price in it.
Broker commissions are a percentage of premium, and premium is now declining for the eighth consecutive quarter. This is the mechanism that turns a mediocre deal into a bad one, and it is entirely absent from the deal presentation.
Quantify the exposure. USI carries ~$3bn of revenue at a ~26% standalone EBITDA margin. Rate-driven revenue drops through at very high incremental margin — a rate cut costs the broker nothing to service. If USI's organic simply travels the path Brown & Brown has already travelled, from +5% to −1%, that is six points of revenue, ~$180m, at ~70% flow-through: $126m of lost EBITDA, equal to 32% of the entire synergy target. Two years of that and the cycle has cancelled the deal's rationale outright.
Meanwhile $1.03bn of annual interest does not soften. That asymmetry — fixed financing cost against cyclical, rate-linked revenue, at 4.8x leverage — is the actual risk in this transaction, and it is not in the multiple, the synergy number, or the accretion date.
Of $395m in net synergies, $321m are revenue synergies — the least reliable category in brokerage, and Aon already has evidence of the failure mode on its own platform.
Cost synergies in a broker merger are real and bankable: overlapping offices, duplicated back office, consolidated carrier relationships. Revenue synergies require producers to stay and cross-sell. A brokerage book is not a factory; it is a relationship, and it leaves in a person's briefcase. In June 2026 — two years into the NFP integration — five specialty executives left Aon's NFP platform for Relation Insurance. Aon has budgeted up to $400m of retention and performance incentives against exactly this risk, which is an honest admission of how the number could break.
Note the disclosure asymmetry: Aon quantified revenue synergies to the million ($321m) but has disclosed no producer-retention assumption at all. My opinion: haircut the revenue synergies by half and the full-run-rate accretion falls from $0.33 to roughly $0.08 per share. The deal becomes a wash.
Aon says it "expects to maintain" Baa2/A-. S&P's own published downside trigger fires well below where Aon plans to operate.
In its November 14, 2025 rating action — the one that restored Aon's outlook to Stable after the NFP deleveraging — S&P wrote its downside scenario explicitly: it could lower ratings within 24 months if leverage is "sustained at around 3x or above and FFO to debt below 25%." Aon's plan is 4.8x at close, returning to a company-defined 2.8–3.0x objective in roughly 24 months. The two measures are not identical — S&P's is adjusted — but the direction is unambiguous: this deal consumes every basis point of headroom S&P restored nine months ago, and then some.
S&P's base case also assumed $2.5–3.5bn of Aon buybacks in 2026. Aon has now suspended them. That single change removes ~3.9% of annual share-count reduction and is, by itself, roughly half of today's share-price move.
My opinion, stated as a falsifiable prediction: S&P moves Aon to A-/Negative within 30 days, and there is a ~35% probability of an actual downgrade to BBB+ within twelve months if organic growth turns negative. A company cannot promise a rating before the committee has met.
Edmund Reese stepped down as CFO effective immediately on August 17, 2026 — thirteen days before this merger agreement was signed on August 30. Nadin Virani is interim, paid an additional $50,000 a month; an executive search is under way. Aon reaffirmed 2026 guidance on the way out, and Reese remains a senior adviser through August 2027.
I do not treat this as evidence of anything hidden. I treat it as execution risk with a price. The largest debt raise in Aon's history, ~$18bn across a range of maturities into a widening-spread market, will be negotiated and priced by an interim finance chief who has been in the seat for two weeks. Sequencing matters: the CFO left, then the deal was signed. Not the reverse.
At $329.77 Aon trades at roughly 18.1x my post-deal 2027 adjusted EPS of ~$18.20 — a ~12% discount to a peer group at 20–22x, which is about what 4.8x leverage, no buyback and an interim CFO are worth. That is fair, not cheap. The screen looks cheaper than it is only because consensus 2027 numbers have not been cut yet. They will be, over the next three weeks, and stocks rarely bottom before the estimate cuts land.
| Entry zone | $332–348 (sell longs, or short into any relief bounce) |
|---|---|
| Target | $298 (−9.6% from $329.77; below the Feb 12, 2026 low of $304.59) |
| Invalidation | Weekly close above $355.50 — back above the pre-announcement close of $355.40, meaning the market has ruled the deal fine |
| Timeframe | 1–3 months |
| Conviction | HIGH CONVICTION — three independent signals: unrevised 2027 estimates plus a zero-buyback year; a deepening soft market with a negative-organic comp print; unresolved ratings risk against a published S&P trigger |
| Audience | Holders should trim into strength. Outright shorts are a modest-return trade on a 0.69-beta name — size accordingly, half position |
The buy leg: I become a buyer at $290–305, target $360, invalidation weekly close < $278, 6–12 months. That is ~16x post-deal 2027 for a 35%-EBITDA-margin, 42%-ROE, recession-resistant compounder with a management team that has actually delevered 3.7x→2.5x once before. At that price I want it. At $330 I do not.
These two legs are sequential, not contradictory: sell here, bid 10% lower. If the stock never reaches $290–305, I miss it, and that is an acceptable outcome.
| Scenario | Weight | Measurable trigger | AON |
|---|---|---|---|
| Bear (my base) Estimate cuts land, credit outlook goes negative, soft market bites | 55% | Any 2027 consensus adjusted EPS print below $18.75, or S&P/Moody's outlook to negative within 45 days, or Q3 organic (late Oct) at 4% or below | $295–305 |
| Base — muddle Debt prices acceptably, organic holds, agencies affirm | 30% | Q4 bond deal prices at a blended coupon under 5.50% and Q3 organic holds at 5% | $320–345, chopping |
| Bull Rate cycle turns, casualty pricing firms, cross-sell shows up | 15% | 10-year below 4.30% and Q4 2026 organic at 6% or better | $360–380 |
Specific and measurable. Any two of these firing means I close the short and move to the buy leg early.
All equity and crypto prices intraday, fetched 16:00–16:05 UTC (12:00–12:05 pm ET), Monday August 31, 2026. US market open at time of writing; these are not closing prices. Rates and commodities as displayed on Investing.com at 12:01 pm ET.
| Instrument | Level | Change | Note |
|---|---|---|---|
| AON | $329.77 | −7.21% | Prev close $355.40; 52wk $304.59–$382.34 (high Jul 28, 2026); mkt cap $74.2bn; ~225m shares; beta 0.69; TTM EPS $18.14; ROE 42.6%; div yield 0.75% |
| KKR | $110.63 | +1.79% | 52wk $82.67–$152.10; TTM EPS $3.31 |
| AJG / WTW / BRO | $261.92 / $338.37 / $72.08 | −2.11% / −1.57% / −1.68% | TTM P/E 41.7 / 20.2 / 19.5 |
| SPY / QQQ / IWM | $765.66 / $714.12 / $293.27 | −0.48% / −0.32% / −0.84% | IWM through EQ-IWM-1 entry |
| US 10Y / 30Y / 5Y | 4.763% / 5.262% / 4.502% | +4.1 / +5.4 / +2.0 bp | 10Y above my 4.70% AI-multiple compression trigger |
| HYG / LQD / TLT | $79.70 / $106.13 / $82.31 | −0.05% / −0.21% / −0.69% | HYG 2.1% above the $78.00 credit-regime trigger |
| BTC / ETH | $78,569 / $2,468 | −0.30% / −0.48% | Fear & Greed 62 (Greed), down from 74 on Aug 25; BTC dominance 59.2% |
| Brent / WTI | $90.57 / $85.52 | +5.17% / +2.54% | US–Iran escalation; relevant to EQ-FRO-1 |
| Input | Value | Source / basis |
|---|---|---|
| Purchase price (net) | $16,700m | 8-K, disclosed |
| Transaction / integration / retention costs | $160m / $550m / $400m | 8-K, disclosed |
| Total new debt raised | $18,100m | $17.0bn price + $1.11bn costs; Aon states it funds "the transaction, as well as related transaction expenses and other costs" with new debt |
| USI synergized adj. EBITDA | $1,152–1,200m | 8-K; range reflects rounding vs. the exact figure implied by 14.5x |
| Net synergies | $395m | 8-K ($321m revenue + $280m cost, netted) |
| USI standalone adj. EBITDA | $757–805m; midpoint $781m | Derived. Implies ~26% margin on $3bn revenue — plausible for a sponsor-owned mid-market broker |
| Less ordinary D&A (not acquired intangibles) | $75m | Assumption. Aon's adjusted EPS excludes acquired-intangible amortisation but not ordinary D&A |
| USI adj. operating income | ~$730m | Derived, using the $805m upper standalone figure less D&A |
| Blended coupon | 5.70% | THE LOAD-BEARING INPUT. Basis: 10Y 4.763% + ~100bp IG spread (S&P Q3 2026); Aon's existing 5.45% 2034s and 5.75% 2054s; skewed across maturities |
| Effective tax rate | 19.5% | Aon's historical range, Irish domicile |
| Diluted shares | 225m | $74,163m market cap ÷ $329.77 |
| Pre-deal 2027 adj. EPS baseline | ~$20.00 | Estimate. H1 2026 actual adj. EPS $8.28 (Q1 $4.47 + Q2 $3.81), FY26 ~$18.30, ~9% growth |
2027 (partial synergies, ~$75m net of dis-synergies): $730m + $75m − $1,032m = −$227m pre-tax → −$183m after tax → −$0.81/share. Add ~$1.00/share of foregone buyback accretion (S&P had modelled $2.5–3.5bn of 2026 repurchases; ~3.9% of share count per year now forgone). Total ~−$1.81, or ~9% below pre-deal 2027 consensus → post-deal 2027 adj. EPS ~$18.20 → 18.1x at $329.77.
Where this could be wrong. The blended coupon is the input that decides the conclusion. At 5.00% the deal is 3.9% accretive at full run-rate and my "barely worth doing" verdict is too harsh — AON would be a hold, not a short, and the $298 target would be wrong. At 6.50% the deal is permanently dilutive and $298 is generous. A secondary risk runs the other way: if USI's true standalone margin is 30% rather than 26% — my derived figure, not a disclosed one — standalone EBITDA is ~$900m, the standalone multiple falls to ~18.5x, and the accretion math improves by roughly $0.40/share. Both sensitivities are checkable against the Q4 bond pricing and the first post-close segment disclosure.
Reconciles the disclosed 14.5x to the ~21x standalone figure used throughout. Shown in full in the second section above; the two derivations differ only in whether the rounded $1.2bn or the exact $1.152bn implied by $16.7bn ÷ 14.5 is used as the synergized base. No figure in this appendix is independent of the body — it is here so the arithmetic can be re-run, not restated.
The comparison table in the body carries the argument. The caution worth isolating: each of these five deals disclosed its multiple on a different basis — synergized trailing (Aon–USI), seller-adjusted estimated at closing (Aon–NFP), pro forma EBITDAC before and after synergies (Gallagher–AssuredPartners), net price to pro forma adjusted EBITDA (Brown & Brown–Accession), undisclosed (Marsh–McGriff). Any cross-deal ranking that ignores this is comparing different quantities. Gallagher is the only acquirer in the group that published both a pre- and post-synergy figure, which is why it is the fair benchmark on both lines.
Brown & Brown's −0.7% Q2 2026 organic figure is reported secondhand and is not linked; verify against the company's 10-Q before relying on it. Aon's investor presentation (Exhibit 99.2) and the August 31 conference call were not read directly; all deal figures above come from the 8-K text and press release.
Disclosure and method. Every price in this note was fetched live at publication; none was recalled. USI's standalone EBITDA, the blended coupon, ordinary D&A, the tax rate and the 2027 EPS baseline are my estimates, labelled as such, and each is stated so it can be checked. Directional views marked as opinion are opinion. This is analysis, not investment advice, and I may be wrong — Section "What would prove me wrong" says exactly how you will know.